JP2009539841A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539841A5
JP2009539841A5 JP2009514336A JP2009514336A JP2009539841A5 JP 2009539841 A5 JP2009539841 A5 JP 2009539841A5 JP 2009514336 A JP2009514336 A JP 2009514336A JP 2009514336 A JP2009514336 A JP 2009514336A JP 2009539841 A5 JP2009539841 A5 JP 2009539841A5
Authority
JP
Japan
Prior art keywords
antibody
administered
amount
fragment
intravenously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009514336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539841A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/013232 external-priority patent/WO2007145941A2/en
Publication of JP2009539841A publication Critical patent/JP2009539841A/ja
Publication of JP2009539841A5 publication Critical patent/JP2009539841A5/ja
Pending legal-status Critical Current

Links

JP2009514336A 2006-06-06 2007-06-05 自己免疫疾患の治療における抗ｃｄ３抗体の投与 Pending JP2009539841A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44762806A 2006-06-06 2006-06-06
US92148506P 2006-06-06 2006-06-06
PCT/US2007/013232 WO2007145941A2 (en) 2006-06-06 2007-06-05 Administration of anti-cd3 antibodies in the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2009539841A JP2009539841A (ja) 2009-11-19
JP2009539841A5 true JP2009539841A5 (enExample) 2010-07-22

Family

ID=38832328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514336A Pending JP2009539841A (ja) 2006-06-06 2007-06-05 自己免疫疾患の治療における抗ｃｄ３抗体の投与

Country Status (7)

Country Link
US (1) US20090258001A1 (enExample)
EP (2) EP2023955A4 (enExample)
JP (1) JP2009539841A (enExample)
AU (1) AU2007258694B2 (enExample)
CA (1) CA2653387A1 (enExample)
NZ (1) NZ573132A (enExample)
WO (1) WO2007145941A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
CA2614640A1 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
WO2010027797A1 (en) * 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
EA032828B1 (ru) * 2008-10-10 2019-07-31 Аптево Рисёрч Энд Девелопмент Ллс Иммунотерапевтические средства против комплекса tcr
US8609364B2 (en) * 2009-05-07 2013-12-17 bioM{tilde over (e)}rieux, Inc. Methods for antimicrobial resistance determination
WO2011050106A2 (en) * 2009-10-20 2011-04-28 Tolerx, Inc. Anti-cd3 antibody dosing in autoimmune disease
WO2011050104A2 (en) * 2009-10-20 2011-04-28 Tolerx, Inc. Methods of using anti-cd3 antibodies to prevent weight gain
MX2012006406A (es) 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP2787078B1 (en) 2011-10-31 2019-05-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
US10202452B2 (en) 2012-04-20 2019-02-12 Aptevo Research And Development Llc CD3 binding polypeptides
CA2880880C (en) * 2012-08-03 2021-01-26 John Mckew Cyclodextrin for the treatment of lysosomal storage diseases
ES2900898T3 (es) 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Anticuerpos biespecíficos inmunoactivadores
CA2947157A1 (en) 2014-05-13 2015-11-19 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
MX2018003292A (es) 2015-09-21 2018-08-01 Aptevo Res & Development Llc Polipéptidos de unión a cd3.
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
US12569477B2 (en) * 2017-06-28 2026-03-10 Mitocholine Ltd Compositions for synergistically enhancing mitochondrial function
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
TW202546002A (zh) * 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
JP7774447B2 (ja) * 2019-06-07 2025-11-21 アディマブ・リミテッド・ライアビリティ・カンパニー 高アフィニティ抗ｃｄ３抗体、ならびにその作製方法及び使用方法
WO2020250940A1 (ja) * 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
WO2021006328A1 (en) 2019-07-10 2021-01-14 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
IL315052A (en) 2022-02-18 2024-10-01 Beren Therapeutics P B C Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658019A (en) 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
JP2546544B2 (ja) * 1989-10-27 1996-10-23 アーチ ディベラップメント コーポレイション 免疫強化を促進するための方法と組成物
US6406696B1 (en) * 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) * 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
JP3111024B2 (ja) * 1995-07-19 2000-11-20 キヤノン株式会社 カラーフィルタの製造装置及び製造方法及び表示装置の製造方法及び表示装置を備えた装置の製造方法
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US7041289B1 (en) 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
CA2224256C (en) 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MXPA01007845A (es) * 1999-02-05 2004-06-22 Samsung Electronics Co Ltd Metodo para la recuperacion de la textura de imagenes y aparato para el mismo.
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1567192A4 (en) * 2002-12-05 2006-02-08 Protein Design Labs Inc TECHNIQUES FOR TREATING ULCERO-HEMORRHAGIC RECTO-COLITIS WITH ANTI-CD3 ANTIBODIES
DE10336334B3 (de) * 2003-08-08 2005-08-04 Cnh Baumaschinen Gmbh Hydraulisches Steuersystem für Baumaschinenen, insbesondere für Bagger
WO2005048935A2 (en) * 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methods of modulating immunity
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
WO2005076965A2 (en) * 2004-02-04 2005-08-25 The Trustees Of Columbia University In The City Of New York Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
CA2569509C (en) * 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
CA2614640A1 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity

Similar Documents

Publication Publication Date Title
JP2009539841A5 (enExample)
Barratt et al. Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria
JP2006506333A5 (enExample)
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2006528626A5 (enExample)
JP2014533279A5 (enExample)
JP2009518441A5 (enExample)
RU2423383C2 (ru) Антитела к ox40l
JP2009500457A5 (enExample)
JP2019178142A5 (enExample)
RU2014105496A (ru) Способы снижения числа эозинофилов
JP2010500360A5 (enExample)
JP2016509582A5 (enExample)
RU2018100129A (ru) Способы лечения подагры
JP2019503387A5 (enExample)
JP2005506331A5 (enExample)
JP2017079785A5 (enExample)
JP2013518912A5 (enExample)
JP2009519257A5 (enExample)
JP2013508392A5 (enExample)
JP2012102122A5 (enExample)
JP2015534578A5 (enExample)
RU2012133522A (ru) Новое применение соединений ил-1 бета
JP2013501814A5 (enExample)
JP2003517461A5 (enExample)